PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Cirena Launches High-Purity Long RNA to Accelerate CRISPR and Genome-Editing Research

Breakthrough technology delivers 100–400nt RNA with exceptional purity, enabling faster design cycles and improved editing precision

Cirena, pioneers in long and ultra-long, high purity RNA synthesis for gene editing and functional genomics, today announced its public launch following successful delivery of high-quality long RNA to leading academic and pharmaceutical research teams across the U.S., Europe, and Japan.

As CRISPR and prime editing applications advance, researchers are increasingly turning to longer guide RNAs and related constructs to boost editing efficiency and reduce off target effects. Historically, obtaining long RNA meant stitching shorter oligos together, investing significant time in purification, or waiting months for delivery—delays that slow innovation. Cirena eliminates these bottlenecks by rapidly producing long RNA with uncompromised quality, enabling scientists to iterate faster and achieve more precise outcomes.

“As RNA science evolves, researchers are eager to unlock the potential of longer gRNAs for improved editing precision,” said Marv Caruthers, Co-Founder of Cirena. “Cirena enables this exploration by delivering high quality long RNA rapidly, thus eliminating the delays that have historically slowed innovation.”

“While many great companies reliably deliver short RNA, producing long RNA without compromising integrity is notoriously difficult,” commented John Rinn, LincSwitch CEO. “Cirena proved that they can reliably deliver 150nt RNA with exceptional quality across the U.S., enabling our team to confidently advance experiments without delays.”

Cirena’s proprietary technology maintains sequence integrity for demanding CRISPR and functional genomics workflows. The company’s streamlined operations reduce turnaround times, allowing researchers to accelerate gRNA, pegRNA, and related designs. With proven logistics and reliable global delivery, Cirena supports academic, pharma, and biotech teams working on CRISPR base and prime editing, oncology research, vaccine development, and gene regulation studies.

Researchers can learn about Cirena’s early customer program or request evaluation materials at www.cirena.com or by contacting RNAtechsupport@cirena.com. Cirena RNA products are intended for research use only.

About Cirena
Cirena provides long and ultra-long, high purity RNA for researchers in therapeutics, gene editing, and functional genomics. The company’s proprietary technology -developed at the University of Colorado Boulder by the teams of Prof. Marvin Caruthers (co founder: Amgen, Applied Bioscience) and Dr. Douglas Dellinger (CU Boulder, Agilent) – enables rapid turnaround of 100+ nt RNA with exceptional purity. Cirena is headquartered at the BioFrontiers Institute at the University of Colorado Boulder.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026